🇺🇸 Vir Biotechnology, Inc.VIR
Get Vir Biotechnology, Inc. filings on Telegram the moment they are published.
Follow Vir Biotechnology, Inc. on TelegramOne tap starts your 30-day free trial. No card needed.
Subject: 8-K Items 7.01, 8.01, 9.01
Overview: Announces Phase 3 ECLIPSE 1 trial results meeting primary endpoint with a 44% response rate for elebsiran and tobevibart in chronic hepatitis delta.
Source: SEC EDGAR · Original filing
Get filings like this in Telegram the moment they are published — for the companies you follow.
Start 30-day trial About Finterest